Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sabeen Mekan"'
Autor:
Cristina Ivanescu, Saby George, Bernard Escudier, Hans J. Hammers, Viktor Grünwald, Sabeen Mekan, Paul Nathan, David Cella, Justin Doan, Brian I. Rini, Marc-Oliver Grimm, Jean Paty, Robert J. Motzer
Publikováno v:
The Lancet. Oncology. 20(2)
In the ongoing phase 3, CheckMate 214 trial, nivolumab plus ipilimumab improved overall survival compared with sunitinib in patients with intermediate or poor risk, previously untreated, advanced renal cell carcinoma. We aimed to assess whether healt
Autor:
Sabeen Mekan, Philippe Barthélémy, Marc-Oliver Grimm, Bohuslav Melichar, Allen C. Chen, Robert E. Hawkins, David F. McDermott, Christian Kollmannsberger, Brian I. Rini, M. Brent McHenry, Megan Wind-Rotolo, Sergio Bracarda, Nizar M. Tannir, Carlos H. Barrios, Toni K. Choueiri, Camillo Porta, Osvaldo Arén Frontera, Bernard Escudier, Robert J. Motzer, Yoshihiko Tomita, Justin Doan, Howard Gurney, V. Neiman, Frede Donskov, Alain Ravaud, Pamela Salman, Hans J. Hammers, Daniel Castellano, Thomas Powles, Saby George, Elizabeth R. Plimack, Padmanee Sharma
Publikováno v:
CheckMate 214 Investigators 2018, ' Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma ', The New England Journal of Medicine, vol. 378, no. 14, pp. 1277-1290 . https://doi.org/10.1056/NEJMoa1712126
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
NEW ENGLAND JOURNAL OF MEDICINE
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced rena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be20ad4dc575b4b2b082a5f7053e6c4
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html
https://pure.au.dk/portal/da/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renalcell-carcinoma(9d613da7-a490-4e1e-940a-79cc1309b512).html